AIM ImmunoTech is trading 5.9% up at $0.25 on a light-liquidity bounce despite no fresh news or fundamental catalysts.
- The move follows several choppy, low-priced sessions and appears to be idiosyncratic, as the broader biotech sector is currently trading lower.
- There are no new company-specific headlines, regulatory filings, clinical updates, or analyst calls to account for the price action.